Afamelanotide
Also known as Scenesse, Melanotan I, Melanotan-1, MT-1, CUV1647, NDP-MSH
A synthetic alpha-MSH analogue approved as an implant for one rare light disease in adults. Melanotan I was a code name; products sold as it are not the drug.
Afamelanotide is a prescription medicine for one rare disease. As Scenesse, an implant placed under the skin by a healthcare professional, it is approved in the United States and the European Union for adults with erythropoietic protoporphyria (EPP), an inherited condition in which light on the skin causes severe pain (source, source). What FDA accepted, on evidence it called borderline, is that it lets people with EPP spend more time in direct sunlight without pain. The label still tells patients to keep up their sun and light protection.
What it is
Afamelanotide is a synthetic version of alpha-melanocyte-stimulating hormone (alpha-MSH), the hormone that drives skin tanning. FDA describes it as a 13-amino acid linear peptide that binds mainly to the melanocortin 1 receptor (source). Two of its residues, norleucine and a D-form phenylalanine, have no standard one-letter code, so no sequence is shown here.
FDA's review lists Melanotan-1 (MT-1) and CUV1647 among its code names (source). Melanotan II is a different molecule: shorter, cyclic, and not approved by any regulator checked on its own page. The approval covers Clinuvel's implant for its labelled use. It says nothing about the identity, purity or safety of products sold online as "Melanotan 1", and no published analysis of such products was found.
Where the evidence stands
Outside EPP, the evidence is thin. In vitiligo there is one published open-label randomised trial against light therapy alone (source), and a phase 3 trial that has not reported (source). Other light-sensitivity conditions rest on a few patients or on unpublished trials.
The UK, Australian and anti-doping status of afamelanotide could not be retrieved for this page, so none is given.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Human randomised trialSupportive / Low confidence
In the pivotal US trial in erythropoietic protoporphyria (CUV039, 94 randomised, 180 days), afamelanotide increased pain-free time in direct sunlight, but FDA judged the result borderline.
The primary endpoint was hours spent in direct sunlight on days without pain. The published paper reports medians of 69.4 hours with afamelanotide against 40.8 hours with placebo (P=0.04), in the patients who returned diaries. FDA's analysis of everyone randomised and treated gave 64.1 against 40.5 hours with a p-value of 0.055, and a second sensitivity analysis gave 0.091. FDA also notes that the applicant's first study report gave a p-value of 0.107, before the treatment assignments of two participants, transcribed wrongly, were corrected. FDA called it the most reliable trial in the programme but said it does not clearly meet the significance threshold.
Tested in humans under randomised, controlled conditions.
- Sponsored by Clinuvel, the developer.
- The measured benefit is time in the sun without pain, not fewer or milder reactions.
PMID 26132941fda-review-scenesse-2019fda-label-scenesse-2026
- Human randomised trialSupportive / Low confidence
In the EU trial in erythropoietic protoporphyria (CUV029, 74 patients, 270 days), pain-free time in direct sunlight was longer with afamelanotide, but EMA classed the trial as not compliant with Good Clinical Practice.
Median pain-free time in direct sunlight was 6.0 hours with afamelanotide against 0.8 hours with placebo (P=0.005), and the paper reports fewer phototoxic reactions, 77 against 146 (P=0.04). FDA found the applicant's reaction analyses biased, because they counted mild pain scores as zero, and 'not sufficient to support efficacy claims'; with every pain score counted as observed, total severity gave p=0.107. Endpoints counting sunlight hours at any level of pain showed no difference (p=0.496 and p=0.97). FDA's review records that the primary endpoint was changed before unblinding, and that EMA classed the study as not compliant with Good Clinical Practice, citing the diary design, statistical planning and the handling of source documents. FDA still counted it as support for the US result.
Tested in humans under randomised, controlled conditions.
- Sponsored by Clinuvel.
- The reported difference is a few hours over nine months.
- Human randomised trialNo effect found / Moderate confidence
Across the US trials, afamelanotide did not reduce the severity of phototoxic reactions, the outcome the programme was first designed to show.
FDA states that the third trial, CUV030 (77 patients), did not reach statistical significance on its prespecified endpoint, the severity of phototoxic reactions, and that this endpoint 'was not sensitive to any treatment effect' between afamelanotide and vehicle. The approved indication therefore rests on pain-free time in sunlight instead. The ClinicalTrials.gov record for CUV030 now lists a sunlight endpoint as primary, which FDA describes as defined after the fact.
Tested in humans under randomised, controlled conditions.
- The EU trial's paper reports fewer reactions, but FDA judged that analysis biased and not sufficient to support efficacy claims.
- Human randomised trialSupportive / Low confidence
In vitiligo, an open-label randomised trial (55 adults) found more repigmentation when afamelanotide was added to narrowband UV-B than with UV-B alone. It is not approved for vitiligo by any regulator found.
Patients were randomised to narrowband UV-B with afamelanotide (28) or UV-B alone (27). Response was better with the combination at day 56 (P<.05), and repigmentation at day 168 was 48.64% against 33.26%. The improvement was seen in skin phototypes IV to VI, with no significant difference in phototype III. There was no placebo implant. A phase 3 trial with an estimated 200 patients, also open label and against UV-B alone, has an estimated primary completion of December 2025 and has posted no results.
Tested in humans under randomised, controlled conditions.
- Open label, with a drug that visibly darkens skin, so neither patients nor assessors were blinded.
- Only the abstract was read.
- Human randomised trialSupportive / Low confidence
In fair-skinned healthy volunteers (65 completed), injections of the same molecule increased skin melanin and reduced markers of UV damage. No study found measured skin cancer as an outcome.
This randomised trial gave the molecule by injection. Melanin density increased significantly in all treated volunteers, by an average of 41% in those who burned most easily (P<0.0001 against placebo). Sunburn cells after UV exposure fell by more than half in that group, and thymine dimers, a form of UV damage to DNA, fell by 59% (P=0.002).
Tested in humans under randomised, controlled conditions.
- Melanin, sunburn cells and thymine dimers are surrogates. None of them is skin cancer.
- It is the basis of a hypothesis, not of an approval: no regulator found has approved afamelanotide for tanning or sun protection.
- Only the abstract was read.
- Human case reportInsufficient evidence / Very low confidence
Outside erythropoietic protoporphyria and vitiligo, the human data are pilots and unpublished trials.
In solar urticaria, five patients given one implant in winter had a smaller weal response across the wavelengths tested at 60 days (P=0.049 against their own baseline); the rise in the light dose needed to trigger a reaction did not reach significance (P=0.058). A placebo-controlled trial of 31 people with polymorphic light eruption was run in 2010, first registered on ClinicalTrials.gov in January 2021, and has not been published.
One or a few individual cases. Cannot show whether an effect is general.
- Five patients with no control group; the authors call for further study.
- A trial registered a decade after it ended, and never published, cannot be weighed.
Reported and theoretical risks
- Human RCTmild
Implant site reactions, nausea and other common adverse reactions
Pooling the three EPP trials, FDA's label lists implant site reactions in 26 of 125 people (21%) against 12 of 119 on vehicle (10%), nausea in 24 (19%) against 17 (14%) and fatigue in 7 (6%) against 3 (3%). The current label and FDA's 2019 review give slightly different counts for oropharyngeal pain and cough, so those are not repeated here. The trial paper describes adverse events as mostly mild, and serious adverse events as not thought to be related to the drug.
- Mechanismserious
Serious hypersensitivity reactions, including anaphylaxis
The label states that serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use, and contraindicates the implant after a severe hypersensitivity reaction to afamelanotide or its excipients. FDA approved this change to the contraindications in August 2024, following a safety signal letter it sent in September 2022.
- Mechanismmild
Darker skin and darkening of existing moles and freckles
The label states that it may cause generalised increased skin pigmentation and darkening of pre-existing moles and freckles, and recommends a full body skin examination twice a year to monitor existing and new pigmented lesions. In the pooled trials, skin hyperpigmentation was reported in 5 people (4%) and none on vehicle, and melanocytic nevus in 5 (4%) against 2 (2%).
- Mechanismunknown
Long-term skin cancer risk not established
FDA's review states that 'there is no accurate animal model to address the potential of afamelanotide to induce melanomas'. As a condition of approval, FDA required a registry following US patients for at least eight years, with skin cancer, melanoma and non-melanoma, among the primary adverse events of interest; its final report is due in March 2031.
- Mechanismunknown
Not established in children or adolescents
The US label states that safety and effectiveness have not been established in pediatric patients. In the EU, an application to extend use to adolescents rested on a registry with 7 people aged 15 to 17; it was withdrawn in April 2024, when EMA's provisional opinion was that it could not have been authorised.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAapproved limited indication
FDA approved Scenesse (afamelanotide) implant on 8 October 2019 'to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)'. Approval required a thorough QT study and an eight-year US safety registry. In August 2024 FDA approved a revision of the contraindications after a hypersensitivity safety signal; the indication did not change. Read from the approval letter, the 2024 supplement letter and the current label.
As of 8 October 2019. Source
EUEMAapproved limited indication
The European Commission authorised Scenesse on 22 December 2014 for 'Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)', and states that it 'was authorised under exceptional circumstances'. It is under additional monitoring. Read from EMA's product page.
As of 22 December 2014. Source
EUEMAnot approved
For adolescents. Clinuvel withdrew an application to extend use to adolescents, first aged 12 to 17 and later narrowed to 15 to 17 and over 60 kg, on 24 April 2024; EMA's provisional opinion at the time was that Scenesse could not have been authorised for adolescents with EPP. Read from EMA's question-and-answer document on the withdrawal.
As of 24 April 2024. Source
Related peptides
- Melanotan IIA synthetic cyclic peptide sold for tanning
Sources
- 1. Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. The New England Journal of Medicine. 2015. PubMed 26132941(open access)
- 2. NDA 210797 Scenesse (afamelanotide) Multi-disciplinary Review and Evaluation. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 2019. View source(open access)
- 3. SCENESSE (afamelanotide) implant prescribing information, NDA 210797. U.S. Food and Drug Administration (openFDA drug label). 2026. View source(open access)
- 4. Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) (CUV030). ClinicalTrials.gov. 2010. NCT01097044(open access)
- 5. Lim HW et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatology. 2015. PubMed 25230094
- 6. A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo (CUV105). ClinicalTrials.gov. 2023. NCT06109649(open access)
- 7. Barnetson RS et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. Journal of Investigative Dermatology. 2006. PubMed 16763547
- 8. Haylett AK et al. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. British Journal of Dermatology. 2011. PubMed 20969564
- 9. Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE) (CUV032). ClinicalTrials.gov. 2021. NCT04704713(open access)
- 10. NDA 210797/S-007 supplement approval letter, Scenesse (afamelanotide). U.S. Food and Drug Administration. 2024. View source(open access)
- 11. NDA 210797 approval letter, Scenesse (afamelanotide) implant, 16 mg. U.S. Food and Drug Administration. 2019. View source(open access)
- 12. Withdrawal of application to change the marketing authorisation for Scenesse (afamelanotide). European Medicines Agency (EMA/243052/2024, EMEA/H/C/002548/II/0044). 2024. View source(open access)
- 13. Scenesse (afamelanotide): EPAR overview page. European Medicines Agency. 2026. View source(open access)